Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.


Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Susac syndrome

Other Names for this Disease
  • Retinocochleocerebral vasculopathy
  • SICRET (small infarction of cochlear, retinal, and encephalic tissue) syndrome
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.


Newline Maker

How might Susac syndrome be treated?

Early, aggressive, and sustained treatment of Susac syndrome is recommended to avoid or minimize neurological damage, hearing loss, and/or vision loss. Treatment includes medications that suppress the activity of the immune system (immunosuppressive agents) such as steroids and intravenous immunoglobulins. Other drugs may also be necessary.[1][2][3]
For those with significant hearing loss, a specific type of hearing aid called a cochlear implant may be an option.
Last updated: 4/25/2011

  1. Susac syndrome. Orphanet Database. Accessed 4/25/2011.
  2. Susac JO, Egan RA, Rennebohm RN, Lubow M. J Neurol Sci. June 15, 2007; Accessed 12/18/2008.
  3. Rennebohm, Robert; Susac, John. Journal of Neurological Sciences. February 26,2007; Accessed 1/1/1900.

Clinical Trials & Research for this Disease

  • lists trials that are studying or have studied Susac syndrome. Click on the link to go to to read descriptions of these studies.
  • The Research Portfolio Online Reporting Tool (RePORT) provides access to reports, data, and analyses of research activities at the National Institutes of Health (NIH), including information on NIH expenditures and the results of NIH-supported research.  Although these projects may not conduct studies on humans, you may want to contact the investigators to learn more. Currently there is a research study titled Endothelial-Reactive Antibodies: A diagnostic test for Susac's syndrome. Click on the study title for further information on the study.